Detail akcie Amarin Sp ADR online

Business Summary: Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Amarin Corporation PLC revenues decreased 26% to $42M. Net loss increased 58% to $15.7M. Revenues reflect Licensing and royalty revenue decrease of 28% to $982K. Higher net loss reflects Development and commercialization of VASCEPA segment loss increase of 23% to $16.8M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.49 to -$0.04.